ストックスクリーナーアプリを入手
2.07
5.08%
0.10
プレマーケット:
2.11
0.04
+1.93%
Dare Bioscience Inc (DARE) 最新ニュース
Daré Bioscience issues updated investor corporate presentation - MSN
Daré Bioscience Issues Updated Investor Corporate Presentation - TipRanks
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Is Dare Bioscience Inc (DARE) a opportunity to investors? - uspostnews.com
Viagra for women rolling out in select states - NewsNation
A History of Outperforming Analyst Forecasts and Beating the Odds: Dare Bioscience Inc (DARE) - setenews.com
‘Viagra’ for women hits the shelves – 30 years after men got little blue pills - AOL.com
Sildenafil cream for female sexual arousal disorder available to prescribe in select states - Urology Times
DARE to PLAY sildenafil cream becomes commercially available for women in select states - Contemporary OB/GYN
Dare Bioscience (DARE) Launches Prescription for Women's Topical Arousal Cream - GuruFocus
Daré Bioscience Launches First-Ever Sildenafil Cream for Women, DARE to PLAY™ Sildenafil Cream, Enhancing Female Arousal and Sexual Health - Quiver Quantitative
Daré Bioscience (NASDAQ: DARE) starts 503B DARE to PLAY cream access in select states - Stock Titan
Viagra goes pink (finally!): First-of-its-kind cream promises to jump-start arousal in women - New York Post
Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits - Investing.com Canada
DARE: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 Targe - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer By Investing.com - Investing.com Canada
Dare Bioscience (DARE) Regains Ovaprene Rights from Bayer - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer - Investing.com
Dare Bioscience announces return of rights to Ovaprene phase 3 program ongoing positive interim data - marketscreener.com
Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data - TradingView — Track All Markets
Daré Bioscience (NASDAQ: DARE) regains Ovaprene rights after Phase 3 interim data - Stock Titan
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization - Sahm
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
[1-A] Dare Bioscience, Inc. SEC Filing - Stock Titan
Daré Bioscience receives $3.6 million grant payment for contraceptive work By Investing.com - Investing.com Nigeria
DARE Secures Additional $3.6 Million from Gates Foundation - GuruFocus
Daré Bioscience Receives $3.6 Million in Additional Grant Funding - The Manila Times
Daré Bioscience receives $3.6 million grant payment for contraceptive work - Investing.com
Dare Bioscience (NASDAQ:DARE) Stock Passes Below 200-Day Moving Average – What’s Next? - Defense World
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Str - GuruFocus
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Daré Bioscience (DARE) Q3 2025 Earnings Transcript - AOL.com
Transcript : Daré Bioscience, Inc., Q3 2025 Earnings Call, Nov 13, 2025 - MarketScreener
Earnings call transcript: Dare Bioscience Q3 2025 sees mixed stock reaction - Investing.com Nigeria
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
DARE Bioscience Prepares for Launch of Sildenafil Cream - GuruFocus
Daré Bioscience Q3 2025 Financial Results and Corporate Update - TradingView
Daré (NASDAQ: DARE) to launch DARE to PLAY Sildenafil Cream in December via 503B pathway - Stock Titan
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
What to Expect from Dare Bioscience's Earnings - Benzinga
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Re - GuruFocus
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result - Yahoo Finance
Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream, November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health - MarketScreener
Multi asset correlation models including Daré Bioscience Inc.Product Launch & AI Powered Market Entry Ideas - newser.com
Dare Bioscience (DARE) to Host Webinar on Innovative Sildenafil Cream - GuruFocus
Daré Bioscience Highlights Commercial Launch Readiness for - GlobeNewswire
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - The Manila Times
Daré Bioscience to Host Third Quarter 2025 Financial - GlobeNewswire
Daré Bioscience (NASDAQ: DARE) hosts financial results call Nov 13 at 4:30 p.m. ET - Stock Titan
Dare Bioscience (DARE) to Release Earnings on Thursday - Defense World
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):